Kyverna Therapeutics, INC Form 4 insider transactions

Director Ian T. Clark acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.

Director Fred E. Cohen acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.

Director Beth Seidenberg acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics.

Executive Chairperson Christi Shaw disposed of 4,194 shares of Kyverna Therapeutics common stock to satisfy tax obligations.

Director Mert Aktar acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. reports that Chief Financial Officer Gregory S. Martini was granted stock options on May 18, 2026.

Kyverna Therapeutics reports a significant stock option grant to Chief Commercial Officer Nadia Dac, with vesting over four years.

Kyverna Therapeutics' Chief Financial Officer, Marc Grasso, received restricted stock units and stock options as part of his compensation package.

Kyverna Therapeutics CEO Warner Biddle received substantial restricted stock units and stock options, aligning executive interests with long-term company performance.

Kyverna Therapeutics, Inc. reported equity grants to its Chief Medical & Development Officer, Naji Gehchan, including 18,000 restricted stock units and options for 105,000 shares.

Kyverna Therapeutics Director Andrew Craig Miller acquired 11,006 restricted stock units and 42,945 stock options, signaling increased alignment with shareholder interests.

Kyverna Therapeutics director Sravan Kumar Emany acquired 11,006 restricted stock units and 42,945 stock options.

Kyverna Therapeutics' Chief Technology Officer, Mayobanex Pujols, was granted 300,000 stock options with an exercise price of $8.08.

Kyverna Therapeutics' Executive Chairperson, Christi Shaw, acquired 54,301 shares of common stock and 185,000 stock options through new equity awards.

Kyverna Therapeutics Director Beth Seidenberg acquired 133,333 shares of common stock at $7.50 per share, increasing her beneficial ownership.

Westlake BioPartners, a 10% owner and director, acquired 133,333 shares of Kyverna Therapeutics common stock at $7.50 per share, increasing its indirect beneficial ownership.

Kyverna Therapeutics' Chief Technology Officer, Karen Marie Walker, exercised stock options and subsequently sold common stock under a pre-arranged 10b5-1 plan.

Kyverna Therapeutics, Inc. Chief Financial Officer Marc Grasso was granted 450,000 stock options with an exercise price of $3.07, aligning his interests with shareholder value.

Kyverna Therapeutics, Inc. Director Christi Shaw has increased her beneficial ownership in the company through the acquisition of 16,634 shares of common stock and options to purchase an additional 65,351 shares, signaling strong alignment with shareholder interests.

Kyverna Therapeutics, Inc. Director and 10% owner Beth C. Seidenberg reported the acquisition of 16,634 restricted stock units and 65,351 stock options, alongside significant indirect holdings, as part of a recent SEC Form 4 filing.

Kyverna Therapeutics, Inc. Director Daniel K. Spiegelman was granted 16,634 shares of common stock as restricted stock units and options to purchase 65,351 shares of common stock.

Kyverna Therapeutics, Inc. director Mert Aktar was granted 16,634 restricted stock units and options to purchase 65,351 shares of common stock, aligning his interests with shareholders.

Kyverna Therapeutics, Inc. (KYTX) has reported that Director Ian T. Clark was granted 16,634 restricted stock units and options to purchase 65,351 shares of common stock, aligning his incentives with shareholder value.

Kyverna Therapeutics, Inc. Director and 10% owner Fred E. Cohen reported the acquisition of 16,634 restricted stock units and 65,351 stock options on May 29, 2025, as part of his compensation.

Kyverna Therapeutics CEO Warner Weston Biddle reports the acquisition of stock options.

Ryan Alexander Jones, CFO of Kyverna Therapeutics, reports the acquisition of common stock and stock options.

Karen Marie Walker, Chief Technology Officer of Kyverna Therapeutics, acquired stock options and restricted stock units on April 11, 2025.

Christi Shaw, a director at Kyverna Therapeutics, acquired stock options for 38,679 shares of common stock on February 14, 2025.

Kyverna Therapeutics' Chief Medical & Development Officer, Naji Gehchan, was granted stock options for 425,000 shares.

Director Mert Aktar acquired stock options in Kyverna Therapeutics, according to a Form 4 filing with the SEC.